Physician profile
Steven E Catlett
NPI 1629038047
$5,641.44
in general payments reported to CMS, 2019-2025
28 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $420 · 2021: $1,783 · 2022: $725 · 2023: $254 · 2024: $425 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $914.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $675.78 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $629.16 | 2019-2021 | |
| Abbvie INC. | $565.09 | 2019-2024 | Ubrelvy, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $397.75 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $356.85 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $352.12 | 2021 | |
| Daiichi Sankyo INC. | $284.92 | 2020-2022 | |
| Lilly USA, LLC | $182.29 | 2021-2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.92 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $154.82 | 2020-2022 | |
| Mylan Specialty L.P. | $129.10 | 2019 | |
| Abbott Laboratories | $127.64 | 2019 | |
| Sanofi Pasteur INC. | $89.28 | 2019 | |
| Amarin Pharma, INC. | $87.89 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $85.92 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $80.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.34 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.55 | 2019-2025 | Xifaxan |
| Alkermes, INC. | $57.91 | 2019-2025 | Aristada, Lybalvi |
| Pfizer INC. | $50.12 | 2019-2021 | |
| Medtronic Minimed, INC. | $22.20 | 2020 | |
| Insulet Corporation | $20.23 | 2025 | Omnipod |
| Allergan, INC. | $15.94 | 2019 | |
| Smith+Nephew, INC. | $14.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.56 | 2019 | |
| Medtronic, INC. | $12.59 | 2021 | |
| Cequr Corporation | $12.50 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Catlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.